These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11445503)

  • 21. Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones.
    Takenouchi T; Sakagawa E; Sugawara M
    Antimicrob Agents Chemother; 1999 Feb; 43(2):406-9. PubMed ID: 9925546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Jalal S; Ciofu O; Hoiby N; Gotoh N; Wretlind B
    Antimicrob Agents Chemother; 2000 Mar; 44(3):710-2. PubMed ID: 10681343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
    Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
    J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital.
    Wolter DJ; Smith-Moland E; Goering RV; Hanson ND; Lister PD
    Diagn Microbiol Infect Dis; 2004 Sep; 50(1):43-50. PubMed ID: 15380277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa.
    Wong-Beringer A; Wiener-Kronish J; Lynch S; Flanagan J
    Clin Microbiol Infect; 2008 Apr; 14(4):330-6. PubMed ID: 18190571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. gyrA and parC mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa from Nini Hospital in north Lebanon.
    Salma R; Dabboussi F; Kassaa I; Khudary R; Hamze M
    J Infect Chemother; 2013 Feb; 19(1):77-81. PubMed ID: 22821356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
    Lee JK; Lee YS; Park YK; Kim BS
    Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Mechanisms of pandrug-resistance of Pseudomonas aeruginosa].
    Shen JL; Zhu DM; Wang MG
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1859-62. PubMed ID: 19040025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.
    Hakki M; Humphries RM; Hemarajata P; Tallman GB; Shields RK; Mettus RT; Doi Y; Lewis JS
    Clin Infect Dis; 2019 May; 68(12):2045-2052. PubMed ID: 30256922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G; Pozzetto B; Dorche G
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors and mechanisms of fluoroquinolone resistance in 156 Escherichia coli strains clinically isolated from urinary tract infections.
    Yasufuku T; Shigemura K; Shirakawa T; Nakano Y; Tanaka K; Arakawa S; Kinoshita S; Nishimura K; Kawabata M; Fujisawa M
    Scand J Infect Dis; 2011 Feb; 43(2):83-8. PubMed ID: 20942776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
    Weigel LM; Anderson GJ; Facklam RR; Tenover FC
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3517-23. PubMed ID: 11709333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa.
    Yoshida T; Muratani T; Iyobe S; Mitsuhashi S
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1466-9. PubMed ID: 7979273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens.
    Chenia HY; Pillay B; Pillay D
    J Antimicrob Chemother; 2006 Dec; 58(6):1274-8. PubMed ID: 17040923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
    Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
    Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of gyrA mutation and loss of OprF in the multiple antibiotic resistance phenotype of Pseudomonas aeruginosa G49.
    Pumbwe L; Everett MJ; Hancock RE; Piddock LJ
    FEMS Microbiol Lett; 1996 Sep; 143(1):25-8. PubMed ID: 8807797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
    Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
    J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance and spread of fluoroquinolone resistant uropathogens in hospitalised urological patients.
    Naber KG; Witte W; Bauernfeind A; Wiedemann B; Wagenlehner F; Klare I; Heisig P
    Infection; 1994; 22 Suppl 2():S122-7. PubMed ID: 7927830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.